A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci193790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Brynne Raines und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Biology Program and. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein Phosphatase 2, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The effectiveness of RAS/MAPK inhibitors in treating metastatic KRAS -mutant non–small cell lung cancer (NSCLC) is often hindered by the development of resistance driven by disrupted negative feedback mechanisms led by phosphatases like PP2A. PP2A is frequently suppressed in lung cancer to maintain elevated RAS/MAPK activity. Despite its established role in regulating oncogenic signaling, targeting PP2A with RAS/MAPK to prevent resistance has not been previously demonstrated. In this study, we aimed to establish a treatment paradigm by combining a PP2A molecular glue with a RAS/MAPK inhibitor to restore PP2A activity and counteract resistance. We demonstrated that KRASG12C and MEK1/2 inhibitors disrupted PP2A carboxymethylation and destabilized critical heterotrimeric complexes. Furthermore, genetic disruption of PP2A carboxymethylation enhanced intrinsic resistance to MEK1/2 inhibition both in vitro and in vivo. We developed RPT04402, a PP2A molecular glue that selectively stabilizes PP2A-B56α heterotrimers. In commercial cell lines and in a patient-derived model, combining RPT04402 with a RAS/MAPK inhibitor slowed proliferation and enhanced apoptosis. In mouse xenografts, this combination induced tumor regressions, extended median survival, and delayed the onset of treatment resistance. These findings highlight that promoting PP2A stabilization and RAS/MAPK inhibition presents a promising therapeutic strategy to improve treatment outcomes and overcome resistance in metastatic KRAS -mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular and Molecular Biology Program and.
- Department of Internal Medicine, Division of Genetic Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Rogel Cancer Center, University of Michigan Health, Ann Arbor, Michigan, USA.
- Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Pharmacology and.
- Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Raines, B., Tseng-Rogenski, S., Dowdican, A. C., Peris, I., Hinderman, M., Zawacki, K. P., Barrie, K., Hodges Onishi, G., Dymond, A. M., Luther, T. K., Musser, S., Karaj Majchrowski, B., Brenner, J. C., Ahmed, A., Taylor, D. J., O'Connor, C. M., & Narla, G. (2025). A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci193790
Vancouver
Raines B, Tseng-Rogenski S, Dowdican AC, Peris I, Hinderman M, Zawacki KP, et al. A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci193790
BibTeX
@article{Raines2025,
author = {Raines, Brynne and Tseng-Rogenski, Stephanie and Dowdican, Amanda C and Peris, Irene and Hinderman, Matthew and Zawacki, Kaitlin P and Barrie, Kelsey and Hodges Onishi, Gabrielle and Dymond, Alexander M and Luther, Tahra K and Musser, Sydney and Karaj Majchrowski, Behirda and Brenner, J Chad and Ahmed, Aqila and Taylor, Derek J and O'Connor, Caitlin M and Narla, Goutham},
title = {A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci193790}
}
EUVIMED